US Stock MarketDetailed Quotes

KPTI Karyopharm Therapeutics

Watchlist
  • 6.420
  • +0.280+4.56%
Close Mar 21 16:00 ET
  • 6.420
  • 0.0000.00%
Post 16:13 ET
54.03MMarket Cap-0.46P/E (TTM)

About Karyopharm Therapeutics Company

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Company Profile

SymbolKPTI
Company NameKaryopharm Therapeutics
Listing DateNov 6, 2013
Issue Price16.00
Founded2008
CEOMr. Richard Paulson, M.B.A.
MarketNASDAQ
Employees279
Fiscal Year Ends12-31
Address85 Wells Avenue,Suite 210, 2nd floor
CityNewton
ProvinceMassachusetts
CountryUnited States of America
Zip Code02459-3298
Phone1-617-658-0600
Websitehttp://www.karyopharm.com

Company Executives

  • Name
  • Position
  • Salary
  • Richard Paulson, M.B.A.
  • Director, President and Chief Executive Officer
  • 2.63M
  • Sohanya Roshan Cheng, M.B.A.
  • Executive Vice President and Chief Commercial Officer
  • 1.19M
  • Dr. Reshma Rangwala, M.D.,PhD
  • Head of Research, Executive Vice President and Chief Medical Officer
  • 1.23M
  • Stuart Poulton
  • Executive Vice President and Chief Development Officer
  • 1.11M
  • Kristin Abate
  • Vice President, Chief Accounting Officer, and Assistant Treasurer
  • --
  • Lori Macomber, C.P.A.
  • Executive Vice President, Chief Financial Officer and Treasurer
  • --
  • Michael Mano, J.D.
  • Senior Vice President, General Counsel and Secretary
  • --
  • Dr. Mansoor Raza Mirza, M.D.
  • Independent Director
  • 208.33K
  • Dr. Deepika Rachel Pakianathan
  • Independent Director
  • 148.33K
  • Dr. Zhen Su
  • Independent Director
  • 81.49K
  • Barry E. Greene
  • Lead Independent Director
  • 173.33K
  • Christy J. Oliger
  • Independent Director
  • 138.33K
  • Garen G. Bohlin
  • Independent Director
  • 138.33K
  • Chen Schor, M.B.A.
  • Independent Director
  • 128.33K

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

No. Symbol Price
Tesla
TSLA
248.710
Apple
AAPL
218.270
Meta Platforms
META
596.250
4
Microsoft
MSFT
391.260
5
Petroleo Brasileiro SA Petrobras
PBR
14.160
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.